MAP2K7 and melanoma: Amaria et al. investigated the neoadjuvant BRAF inhibitor dabrafenib and adjuvant MEK inhibitor trametinib against standard of care (SOC) surgical resection plus adjuvant therapy in patients with stage III/IV melanoma harboring BRAF-V600E and BRAF-V600K mutations.